|
|
Post by mnholdem on Jul 25, 2018 4:58:34 GMT -5
You're a bit late on that call, Kastanes, the time to have accepted reality would have been after about 7 or 8 months of crummy sales with Sanofi. At this point, anyone fool can make comments like you do - it's like shooting fish in a barrel. Do you feel proud? If so think again. Now, for those who 3 or so years ago saw what might have been coming (and did come), well, those people are much sharper. There were a few. Now you're just playing the chalk, like anyone can do. I don't even think Feuerstein is piling on at this point. Your angle is just not at all impressive, and that makes you as big a loser as the longs on the board (not financially, but there are more important ways in which you're near the bottom of the totem pole). My fellow longs may not be cold and calculating, but they're genuine! Try it, perhaps in another life. And what if Mike happens to catch lightning in a bottle and turn this thing around? Think he got deleted or hit the self destruct button himself. I'm with ya. Hindsight is clear as $hit. I rode a six figure gain right into a six figure loss. Still here and still believe. The low blows have and will keep coming from all angles. No staff action was taken. ProBoards members do have the choice to delete their own accounts. |
|
|
|
Post by mnholdem on Jul 24, 2018 20:58:50 GMT -5
For BP diabetes companies, science can be an inconvenient truth. They can avoid reality, but will not escape it.
The science will prevail...and CMO Kendall has a lot of science that's been accumulated, is being organized, and will be presented to the medical community. Afrezza is the real deal, a NEW cutting-edge insulin unlike any advance in decades.
 |
|
|
|
Post by mnholdem on Jul 24, 2018 20:47:01 GMT -5
Post by mnholdem on Aug 25, 2017 at 7:15am
It's pretty amazing just how much "how-to" information is available related to using insulin to enhance muscle growth. Once word of Afrezza makes its way into this circle I anticipate that Afrezza will be the preferred method over injections.
Playlist link: www.youtube.com/playlist?list=PLPwYTbwcgvUQ-bMAbViveiMZ_8vCsX-9Z
One of the main reasons athlete may choose Afrezza? Safety! Just yesterday this British journal published a report highlighting the risks:
Insulin abuse on the increase
The number of bodybuilders using insulin to enhance their performance is increasing despite the potentially fatal consequences, researchers have claimed. The drug, used to treat diabetes, is popular because although it is banned by the International Olympic Committee it is extremely hard to detect as it disappears from the bloodstream four minutes after use. Researchers from Hull Royal Infirmary said that although cases of insulin abuse appeared to be isolated, it was apparent that the problem may be becoming much more widespread.
Read more: www.dailymail.co.uk/health/article-191232/Insulin-abuse-increase.html#ixzz4qlj5EHKJ
Read more: mnkd.proboards.com/thread/8457/insulin-use-weightlifters-body-builders#ixzz5ME4ZqJbK
---
Prophetic? Nah...it just made sense that word about Afrezza would get around the gyms. 
|
|
|
|
Post by mnholdem on Jul 24, 2018 20:29:12 GMT -5
|
|
|
|
Post by mnholdem on Jul 24, 2018 8:22:17 GMT -5
Powders are composed of various ingredients. The FDA wants proof that the particulate and API formulation is safe. All new powder medications likely go through the same scrutiny.
|
|
|
|
Post by mnholdem on Jul 23, 2018 9:46:04 GMT -5
Does anybody think that it's significant that MannKind has been running TV advertisement in Canada? |
|
|
|
Post by mnholdem on Jul 23, 2018 9:42:19 GMT -5
I think that it help with the medical community because, like the many patients you often refer to, most doctors don't have the time to research. Whether they read that compliant TI patients showed significant TIR improvement, or that TI insulin resulted in less hypos and severe hypos compared to RAA insulin (another poster) they probably won't go digging into the fine details. They may remember Afrezza outperformed RAA, however, and that's the reason for MannKind publishing.
|
|
|
|
Post by mnholdem on Jul 23, 2018 2:51:24 GMT -5
WTF? If they were on target with their CGM there is no need for the second dose and they are compliant. And the non-compliant TIR was far worse than the Novolog arm - 48% to 55% Afrezza to Novolog (slide 69) For completeness - the compliant arm was about 62% TIR so the compliant users out-performed the RAA arm by about the same amount that the RAA arm TIR out-performed the non-compliant arm The compliance graph on the STAT poster doesn’t have a non-compliant column for RAA so your comparison is faulty because you’re comparing the non-compliant numbers of TI patients to compliant RAA patients. IMO the argument about percentage of compliance is irrelevant anyway. Whether diabetes or cancer, if a patient doesn’t comply with a treatment protocol, whether because of fear, laziness or poor doctor instructions the results will be negatively affected. What is relevant in the STAT trial is that when patients followed the treatment protocol they achieved significantly better TIR control. That’s what MannKind should be (and are) telling the medical community. The rest is just noise. |
|
|
|
Post by mnholdem on Jul 21, 2018 22:09:13 GMT -5
Did Nate talk about insurance issues and alternatives in his interview? I must of missed that part, perhaps one of the moderators should change the title of the thread to the boards opinion on insurance options. I'll just add that the compliance is much easier with no finger sticks and having a dreamboat with an ample daily supply of cartridges in your pocket...compared to the alternative of barbaric, obsolete, and unpredictable methods....ok carry on  If compliance with Afrezza is supposed to be so great why was it so awful for STAT? If you are getting a third of a supervised group non-compliant on a trial lasting just four weeks that is bad. Well, you know how it is...you can’t tell every diabetic what to do. (Isn’t that what you wrote in a separate thread?). |
|
|
|
Post by mnholdem on Jul 21, 2018 21:00:29 GMT -5
Good point. I’m sure if you had to prick and stick yourself multiple times a day that you wouldn’t mind a little non-compliance.
|
|
|
|
Post by mnholdem on Jul 21, 2018 15:38:29 GMT -5
Sooner or later healthcare costs will be based upon compliance, which is where cloud comes in as far as real time monitoring is concerned. Think like credit reporting, you don't want to comply (pay bills on time) then you'll pay more out of yer pocket. I do not want that. I decide. I get to decide. Are we going be come the Borg? Resistance is futile.  |
|
|
|
Post by mnholdem on Jul 19, 2018 9:18:59 GMT -5
Sports, you’ve hit on a key marketing point when you comment on quality of life [inject photo of girl full of syringes]. As important as the new measurements are (eg TIR) they won’t be readily adopted if they are complicated.
Afrezza is the perfect insulin for improving quality of life. Simple and effective.
|
|
|
|
Post by mnholdem on Jul 18, 2018 9:35:06 GMT -5
|
|
|
|
Post by mnholdem on Jul 17, 2018 18:25:55 GMT -5
Wouldn’t Deerfield be subjected to insider trading regulations? I would think that, as part of the debt negotiation, they were made aware of certain pivotal events and when they are likely to transpire. As a major shareholder (holding ~10% of outstanding shares) Deerfield may have their trading hands tied for a period of time.
|
|
|
|
Post by mnholdem on Jul 17, 2018 18:16:23 GMT -5
Spanning the spectrum from foul play to foreplay. No wonder this board has so many followers! Sports, does ALL foreplay end in August? If so, it may be followed by a high five. In fact, I hope there are a lot of high fives by EOY. |
|
